Synergy Pharma Cmn (NASDAQ:SGYP) shares traded 1.75% up during most recent session to reach at the closing price of $1.74. The stock exchanged hands 2.87 Million shares versus average trading capacity of 3.57 Million shares, yielding a market cap of $429.2 Million. Wall Street analysts covering the stock are projecting that the stock will reach $6.24 within the next 52-weeks. The mean target projections are based on 5 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Synergy Pharma Cmn (NASDAQ:SGYP) high price target of $13 and with a conservative view have low price target of $1.2.

Oppenheimer “Downgrades” Synergy Pharma Cmn (NASDAQ:SGYP) in a research note issued to investors on 1/05/18 to Perform.

Additionally on 9/13/17 Citigroup “Maintained” Synergy Pharma Cmn (NASDAQ:SGYP) to Sell setting price target at $2.5 and on 6/01/17 Cantor Fitzgerald “Initiates Coverage On” the stock to Overweight at $11. Furthermore on 4/06/17 Citigroup “Downgrades” the stock to Sell.

On the other hand the company has Relative Strength Index (RSI 14) of 49.9 along with Average True Range (ATR 14) of 0.11, Consequently Synergy Pharma Cmn (NASDAQ:SGYP)’s weekly and monthly volatility is 7.02%, 6.61% respectively. The company’s beta value is at 1.16.

In terms of Buy, Sell or Hold recommendations, Synergy Pharma Cmn (NASDAQ:SGYP) has analysts’ mean recommendation of 2.3. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Synergy Pharma Cmn (NASDAQ:SGYP)’s minimum EPS for the current quarter is at $-0.17 and can go high up to $-0.13. The consensus mean EPS for the current quarter is at $-0.15 derived from a total of 6 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.33 earnings per share for the same quarter during last year.

Previously Synergy Pharma Cmn (NASDAQ:SGYP) reported $-0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.16 by $0.01. The company posted an earnings surprise of 6.3%.

Synergy Pharma Cmn (NASDAQ:SGYP)’s revenue estimates for the current quarter are $12.23 Million according to 5 number of analysts, for the current quarter the company has high revenue estimates of $13.5 Million in contradiction of low revenue estimates of $10.2 Million. For the current year the company’s revenue estimates are $60.1 Million compared to low analyst estimates of $47.37 Million and high estimates of $68 Million according to 5 number of analysts.

Currently Synergy Pharma Cmn (NASDAQ:SGYP)’s shares owned by insiders are 0.3%, whereas shares owned by institutional owners are 45.1%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded -16.26%.

Synergy Pharma Cmn (NASDAQ:SGYP)’s trailing twelve month revenues are $25.3 Million, whereas its price to sales ratio for the same period is 16.96. Its book value per share for the most recent quarter is $-0.16 while its price to book ratio for the same period is 0, as for as the company’s cash per share for the most recent quarter is $0.4, however its price to cash per share ratio for the same period is 4.35. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.